Company's BMB-101 targets drug-resistant epilepsy, aiming for a multibillion-dollar market by treating patients unresponsive to standard anti-seizure medications. Company's phase 2 trial for Absence ...
CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...
Researchers aimed to identify the characteristics, treatment pathways, and outcomes associated with epilepsy with eyelid myoclonia (EEM). Epilepsy with eyelid myoclonia (EEM) is a rare and ...
A randomized, double-blind clinical trial that compared three widely used anticonvulsants for childhood absence epilepsy established that ethosuximide was the most appropriate first-line therapy for ...
Imagine slipping in and out of consciousness hundreds of times per day, staying awake the whole time but having no sense of awareness during these lapses. In children with absence epilepsy, these ...
Yale researchers identify neuronal basis of impaired consciousness in children with absence epilepsy
Imagine slipping in and out of consciousness hundreds of times per day, staying awake the whole time but having no sense of awareness during these lapses. In children with absence epilepsy, these ...
Children referred to a first seizure clinic often see a neurologist epilepsy specialist within 1 week for timely diagnosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback